You are here

Article Text

Article menu

Download PDFPDF

Letters
PostScript
Authors’ reply
Free
  1. H-J Aubin1,
  2. A Bobak2,
  3. J R Britton3,
  4. C Oncken4,
  5. C B Billing, Jr5,
  6. J Gong5,
  7. K E Williams5,
  8. K R Reeves5
  1. 1
    Hôpital Emile Roux, Assistance Publique-Hopitaux de Paris, Limeil-Brévannes, France; Centre d’Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, Paris, France; Assistance Publique-Hôpitaux de Paris, Villejuif, France; INSERM, Paris, France
  2. 2
    Wandsworth Medical Centre, London, UK
  3. 3
    University of Nottingham, Nottingham, UK
  4. 4
    University of Connecticut Health Center, Farmington, Connecticut, USA
  5. 5
    Pfizer Global Research and Development, Groton, Connecticut, USA
  1. Dr H-J Aubin, Centre de Traitement des Addictions, Hôpital Emile Roux, F-94456 Limeil-Brévannes Cedex, France; henri-jean.aubin{at}erx.aphp.fr

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We acknowledge the proposition raised by Dr Rose that a comparison of nicotine replacement therapy (NRT) and varenicline using equal pre-cessation treatment regimens may result in different efficacy outcomes from those found in our trial. However, we would like to reiterate that our open-label comparison of varenicline with NRT was a pragmatic trial based on current treatment regimen recommendations by the manufacturers of the products and in accordance with current recommendations for transdermal NRT use in established health guidelines.1 2

    Dr Rose suggests that the imbalance in pre-cessation treatment between products in our trial reflects a flaw in the design of our study. The objective of this study was to compare …

    View Full Text